BLTE
NASDAQ
$152.84
Belite Bio Inc (BLTE)
Belite Bio, Inc, a clinical-stage biopharmaceutical drug development company, is engaged in the research and development of novel therapies targeting age-related atrophic macular degeneration and autosomal recessive stargardt diseases. The company is headquartered in San Diego, California.
Sector:
Healthcare
Industry:
Biotechnology
Strong Buy
Target: $210.50 (+37.73%)
Market Cap
$5.88B
EPS 5Y CAGR
+24.69%
Free Cash Flow Yield
-0.63%
Beta (5Y)
0.56
Price Chart
Valuation
Market Cap$5.88B
Forward P/E227.27
P/B7.49
Profitability
EBITDA-$84M
EPS-$1.97
Financial Health
Free Cash Flow Yield-0.63%
Growth & Risk
EPS 5Y CAGR+24.69%
Beta (5Y)0.56
Sharpe Ratio1.94